One-Stop cGMP Turnkey Engineering for Biosimilar Drug Production Facilities
Our biosimilar manufacturing plant turnkey project delivery offers fully integrated, regulatory-aligned engineering solutions for end-to-end construction of monoclonal antibody, fusion protein, recombinant protein and biosimilar bulk drug production sites. We cover the full industrial workflow including cell bank management, mammalian cell fermentation, protein capture & multi-step chromatography purification, viral clearance & inactivation, ultrafiltration/diafiltration concentration, sterile formulation, aseptic filling and final packaging, catering to pilot R&D workshops and large-scale commercial biosimilar factories worldwide.
We provide full-lifecycle turnkey services covering process flow simulation and plant layout design, ISO classified GMP cleanroom construction, customized HVAC differential pressure control system, WFI and pure steam utility station, complete bioprocess equipment integration, CIP/SIP closed circulation pipeline system, full-process automated MES & data traceability platform, biohazard waste treatment system, on-site installation and commissioning, regulatory qualification validation, documentation compilation and long-term operator training. All design and engineering practices fully comply with FDA cGMP, EU GMP Annex 1, ICH Q guidelines and local biopharma registration standards to pass official facility audits smoothly.
Distinct from small-molecule pharmaceutical plants, our turnkey design targets the high sterility, low contamination and strict viral safety requirements of biologic manufacturing. Independent zoning for upstream fermentation and downstream purification eliminates cross-product risks; closed single-use or stainless steel bioprocess lines minimize manual intervention and guarantee consistent product purity. Intelligent central monitoring precisely regulates temperature, pH, dissolved oxygen and pressure throughout cell culture and purification stages, ensuring stable batch-to-batch quality for biosimilar raw materials and finished injectable products.
With abundant track records in global biotech plant delivery, we deliver tailor-made schemes for greenfield factory construction, existing biotech plant renovation, and biosimilar production capacity expansion. From initial technical consultation, equipment BOM optimization and drawing output to complete project handover and lifelong after-sales engineering support, we cut down project construction cycles, control overall investment costs and accelerate clients’ biosimilar clinical and commercial launch progress.
Core Advantages
- Full turnkey delivery covering upstream cell culture to downstream aseptic filling for biosimilars
- Strict zoning & isolation layout to prevent cross-contamination and cross-product carryover
- Complete viral safety, CIP/SIP and full data traceability system compliant with biotech regulations
- Customizable capacity design for lab-scale R&D and mass commercial production
- Fully aligned with FDA, EU GMP and ICH biosimilar manufacturing guidelines
- Complete validation document support, on-site commissioning and long-term technical service
